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http://www.biomedcentral.com/1471-2261/14/150RESEARCH ARTICLE Open AccessI(f) current channel inhibitor (ivabradine) deserves
cardioprotective effect via down-regulating the
expression of matrix metalloproteinase (MMP)-2
and attenuating apoptosis in diabetic mice
Shao-Liang Chen1*, Zuo-Ying Hu2, Guang-Feng Zuo1, Ming-Hui Li3 and Bin Li4Abstract
Background: Ivabradine (IVBD), a novel I(f)-channel inhibitor and specific heart rate-lowering agent, is known to
have anti-oxidative activity that promotes endothelial function. However, the molecular mechanism through which
IVBD acts on cardiac function has yet to be elucidated, especially in experimental diabetic animals.
Methods: For this reason, twenty diabetic mice were randomly assigned to IVBD-treated (10 mg/kg/day) and
control (saline) groups. After a 3-month treatment, microarray assay was performed to identify differentia expressed
genes, and cardiac function was measured by echocardiography, with subsequent immunohistochemistry analysis
and western blotting.
Results: Our results showed that ivabradine treatment attenuated the expression and staining score of matrix
metalloproteinase (MMP)-2, induced the dephosphorylation of caspase 3, BAX and MMP-2, and enhanced the
phosphorylation of NF-κB. Ivabradine treatment led to a significant improvement in cardiac function.
Conclusion: Ivabradine significantly improved cardiac function by attenuating apoptosis and inhibiting the
expression and activity of MMP-2 in diabetic mice, which underscored the novel clinical implications of ivabradine
for diabetic patients.
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In 2007, roughly 6% of people were affected worldwide by
diabetes and it is estimated that this will increase to 7.3%
by 2025 [1]. Diabetes, 90% of which is type 2 diabetes
(T2D), is characterized by impaired glucose homeostasis
and decreased insulin activity and insulin resistance [2],
which lead to elevated blood glucose levels and multiple
system complications [3]. Endothelial dysfunction in T2D
leads to obstructive coronary arterial stenosis, which could
be partially prevented and minimized by the administration
of beta-blockers because of their heart rate (HR)-lowering
effect [4]. However, severe side effects from beta-blockers,* Correspondence: chmengx@126.com
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Ivabradine (IVBD), a novel If-channel inhibitor and
specific HR-lowering agent, acts on the sinoatrial node
but does not alter ventricular contractility and vascular
tone, and has been used for certain patients with angina
pectoris or heart failure who are intolerable to beta-
blockers [5]. Theoretically, IVBD treatment should be
beneficial in T2D, unfortunately, this has not been tested
in diabetic state.
Furthermore, previous studies about the mechanisms and
effect of IVBD on endothelial protection in non-diabetic
animals or cells introduced conflict results [6-9], as such fa-
voring eNOS expression and/or the prevention of NO or
H2O2 degradation [6], inhibiting NADPH-oxidase activity,
superoxide release and the renin-angiotensin-aldosterone
system (RAAS) in ApoE−/− mice [7] ,and not up-regulatingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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different to the finding by Walcher et al. [9] who reported
that IVBD inhibits the chemokine-induced migration of
CD4-positive lymphocytes by limiting both PI-3 kinase
activity and the phosphorylation of AKT.
Notably, the biological and molecular effects ofIVBD on
the heart in the diabetic state has not been studied previ-
ously. Accordingly, the present study aims to determine
the improvement in cardiac function after administering
IVBD to diabetic mice and to explore the mechanisms by
which IVBD acts on.
Methods
Preparation of animals
All diabetic mice were male mices purchased from Nan-
jing Experimental Center (Nanjing, China) when they
were 11–12 weeks old and were housed in a temperature
and humidity controlled animal facility with a 12:12 hr
light–dark cycle. All rats were fed Teklad Global 18% Pro-
tein Rodent Diet (Harlan Laboratories Asia, Hongkong,
China) and had free access to water. All protocols in this
study were conducted in accordance with the National
Health guidelines and were approved by the Institutional
Animal Care and Use Committee of Nanjing Medical
University (Nanjing, China).
Grouping of animals
Twenty diabetic mice were randomly divided into two
groups (of 10 rats each): an IVBD-10 group (ivabradine
was added in the diet at a dosage of 10 mg/kg/day for
three months), and a control group (ivabradine was re-
placed with saline, which was administered for 3 months).
Measurement of cardiac function by echocardiography
Before and after 3 months of IVBD or saline administra-
tion, transthoracic echocardiography (TTE) was per-
formed (MyLab25, Esaote, Italy) with a 13 MHz linear
array transducer. Under light anesthesia (ketamine HCl
and xylazine, 75 and 3.5 mg/kg body weight, respectively,
delivered intraperitoneally), the left ventricular (LV) wall
thickness and end-diastolic (LVDd) and end-systolic
diameters (LVDs) were determined from the short-axis
view at the midpapillary level. The total LV mass (LVM)
and corrected LVM were calculated. The LV end-diastolic
and end-systolic volumes were planimetered from the
parasternal long-axis view. The LV ejection fraction
(LVEF) was calculated as (LV diastolic volume – LV
systolic volume)/LV diastolic volume. All echocardio-
graphic investigations were performed according to the
recommendations of the American Society of Echocardi-
ography [10]. In the current study, the intra- and inter-
observer error(s) were calculated according to s = SD/√2.
The intra-observer variability for the measurement of
LVEF was <5%.Tissue samples
At 3 months, 5 animals in each group were sacrificed by
pentobarbital overdose. The hearts were harvested and
rinsed in PBS. Homogenize tissue samples in 1 ml of
TRIZOL Reagent per 50–100 mg of tissue using a power
homogenizer. The sample volume should not exceed
10% of the volume of TRIZOL Reagent used for
homogenization. The cells were then washed and incu-
bated in SmBM+ 0.5% FBS. The reactions were per-
formed in quadruplicates.Cells grown in monolayer
Lyse cells directly in a culture dish by adding 1 ml of
TRIZOL Reagent to a 3.5 cm diameter dish, and pass-
ing the cell lysate several times through a pipette. The
amount of TRIZOL Reagent added is based on the area
of the culture dish (1 ml per 10 cm2) and not on the
number of cells present.Cells grown in suspension
Pellet cells by centrifugation. Lyse cells in TRIZOL Re-
agent by repetitive pipetting. Use 1 ml of the reagent per
5–10 × 106 of animal, plant or yeast cells, or per 1 × 107
bacterial cells. Washing cells before addition of TRIZOL
Reagent should be avoided as this increases the possibil-
ity of mRNA degradation. Disruption of some yeast and
bacterial cells may require the use of a homogenizer.Phase separation
Incubate the homogenized samples for 5 minutes at 15
to 30°C to permit the complete dissociation of nucleo-
protein complexes. Add 0.2 ml of chloroform per 1 ml
of TRIZOL Reagent. Cap sample tubes securely. Shake
tubes vigorously by hand for 15 seconds and incubate
them at 15 to 30°C for 2 to 3 minutes. Centrifuge the
samples at 12,000 × g for 15 minutes at 4°C. Following
centrifugation, the mixture separates into a lower red,
phenol-chloroform phase, an interphase, and a color-
less upper aqueous phase. RNA remains exclusively in
the aqueous phase. The volume of the aqueous phase
is about 60% of the volume of TRIZOL Reagent used
for homogenization.Rna precipitation
Transfer the aqueous phase to a fresh tube. Precipitate
the RNA from the aqueous phase by mixing with isopro-
pyl alcohol. Use 0.5 ml of isopropyl alcohol per 1 ml of
TRIZOL Reagent used for the initial homogenization.
Incu4bate samples at 15 to 30°C for 10 minutes and cen-
trifuge at 12,000 × g for 10 minutes at 4°C. The RNA
precipitate, often invisible before centrifugation, forms a
gel-like pellet on the side and bottom of the tube.
Table 1 RNA yield and quality before and after DNase I treatment
Samples before Dnase I treatment OD260 OD280 OD260/ OD280 RNA concentration(ng/μl)
IVBD-1 17.079 8.765 1.95 683.14
IVBD-2 15.494 7.962 1.95 619.77
IVBD-3 5.603 3.829 1.46 224.11
IVBD-4 11.815 5.889 2.01 472.58
IVBD-5 17.626 8.540 2.06 705.05
Control-1 13.908 7.215 1.93 556.32
Control-2 9.294 4.841 1.92 371.75
Control-3 11.153 5.965 1.87 446.14
Control-4 14.234 7.344 1.94 569.36
Control-5 14.797 7.684 1.93 591.89
Samples after DNase I treatment OD260 OD280 OD260/ OD280 RNA concentration(ng/ul)
IVBD-1 7.994 3.939 2.03 319.76
IVBD-2 6.840 3.493 1.96 273.59
IVBD-3 5.417 2.769 1.96 216.68
IVBD-4 8.579 4.371 1.96 343.16
IVBD-5 12.352 6.073 2.03 494.08
Control-1 4.455 2.307 1.93 178.20
Control-2 4.807 2.405 2.00 192.27
Control-3 10.141 5.244 1.93 405.63
Control-4 10.424 5.408 1.93 416.96
IVBD, ivabradine.
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Remove the supernatant. Wash the RNA pellet once with
75% ethanol, adding at least 1 ml of 75% ethanol per 1 ml
of TRIZOL Reagent used for the initial homogenization.
Mix the sample by vortexing and centrifuge at 7,500 × g
for 5 minutes at 4°C.
Redissolving the rna
At the end of the procedure, air-dry the RNA pellet for
5–10 minutes. Do not dry the RNA by centrifugation
under vacuum. It is important not to let the RNA pellet
dry completely as this will greatly decrease its solubility.
Partially dissolved RNA samples have an A260/280
ratio <1.6. Dissolve RNA in RNase-free water by passingFigure 1 RNA denaturing agarose gel electrophoresis for ivabradine a
as 1–5 and as 11–15.the solution a few times through a pipette tip, and incu-
bating for 10 minutes at 55 to 60°C. RNA can be stored
at −70°C.
Isolation of small quantity rna
Isolation of RNA from small quantities of tissue (1 to
10 mg) or Cell (102 to 104) Samples: Add 800 μl of
TRIZOL to the tissue or cells. Following sample lysis,
add chloroform and proceed with the phase separation
as described in step 2. Prior to precipitating the RNA
with isopropyl alcohol, add 5-10 g RNase-free glycogen
as carrier to the aqueous phase. To reduce viscosity,
shear the genomic DNA with 2 passes through a 26
gauge needle prior to chloroform addition. The glycogennd control groups. Animals in the ivabradine group were numbered
Table 2 Measurements of cardiac function by
echocardiography
Ivabradine (n = 7) Control(n = 6) P value
IVSTd (mm)
Baseline 0.95 ± 0.12 0.89 ± 0.18 0.539
At 3 months 1.09 ± 0.12 0.94 ± 0.15 0.089
IVSTs (mm)
Baseline 1.37 ± 0.17 1.29 ± 0.21 0.468
At 3-month 1.59 ± 0.03 1.24 ± 0.21 0.022
LVDd (mm)
Baseline 3.30 ± 0.31 3.33 ± 0.27 0.932
At 3-month 2.99 ± 0.14 3.24 ± 0.25 0.497
LVDs (mm)
Baseline 2.09 ± 0.17 2.26 ± 0.50 0.436
At 3-month 1.65 ± 0.08 2.22 ± 0.53 0.017
LVPWd (mm)
Baseline 0.92 ± 0.18 0.84 ± 0.12 0.353
At 3-month 1.09 ± 0.09 0.94 ± 0.16 0.067
LVPWs (mm)
Baseline 1.21 ± 0.09 1.18 ± 0.11 0.577
At 3-month 1.42 ± 0.09 1.26 ± 0.14 0.032
EF (%)
Baseline 67.1 ± 6.96 61.6 ± 7.6 0.202
At 3-month 75.7 ± 3.43 54.1 ± 8.3 0.018
FS (%)
Baseline 36.42 ± 5.56 31.66 ± 4.96 0.135
At 3-month 49.33 ± 3.01 27.34 ± 4.87 <0.001
LVM (g)
Baseline 107.55 ± 10.75 99.81 ± 15.88 0.596
At 3-month 85.85 ± 13.04 98.39 ± 27.92 0.309
LVM-corrected(mm)
Baseline 86.04 ± 8.59 79.99 ± 28.77 0.605
At 3-month 66.65 ± 10.51 78.60 ± 22.30 0.230
LVDd (ml)
Baseline 44.84 ± 10.25 51.99 ± 25.65 0.509
At 3-month 48.07 ± 6.69 49.32 ± 28.40 0.911
LVSd (ml)
Baseline 14.42 ± 2.67 19.79 ± 10.24 0.206
At 3-month 11.97 ± 2.02 19.82 ± 11.06 0.091
IVST, inter-ventricular septal thickness; d, end-diastolic; s, end-systolic; LVD,
left ventricular dimension; LVPW, left ventricular posterior wall; EF, eject
fraction; FS, fraction of shortness; LVM, left ventricular mass.
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the RNA. It does not inhibit first-strand synthesis at con-
centrations up to 4 mg/ml and does not inhibit PCR.
Denaturing agarose gel electrophoresis
Heat 1 g agarose in 72 ml water until dissolved, then cool
to 60°C. Add 10 ml 10X MOPS running buffer, and 18 ml
37% formaldehyde (12.3 M). Pour the gel and allow it to
set. The wells should be large enough to accommodate at
least 25 μl. Remove the comb, and place the gel in the gel
tank. Add enough 1X MOPS running buffer to cover the
gel by a few millimeters. To 3 μg RNA, add 3X volumes
Formaldehyde Load Dye. Ethidium bromide can be added
to the Formaldehyde Load Dye at a final concentration of
10 μg/ml. Heat denature samples at 65–70°C for 15 min.
Load the gel and electrophorese at 5–6 V/cm until the
bromophenol blue (the faster-migrating dye) has mi-
grated at least 2–3 cm into the gel.
The 28S and 18S ribosomal RNA bands should be fairly
sharp, intense bands (size is dependent on the organism
from which the RNA was obtained). The intensity of the
upper band should be about twice that of the lower band.
Smaller, more diffuse bands representing low molecular
weight RNAs (tRNA and 5S ribosomal RNA) may be
present. It is normal to see a diffuse smear of ethidium
bromide staining material migrating between the 18S and
28S ribosomal bands, probably comprised of mRNA and
other heterogeneous RNA species. DNA contamination
of the RNA preparation (if present) will be evident as a
high molecular weight smear or band migrating above
the 28S ribosomal RNA band. Degradation of the RNA
will be reflected by smearing of ribosomal RNA bands
(Table 1, Figure 1).
Real-time polymerase chain reaction (RT-PCR) analysis
The extracted RNA was first DNase-treated with RQ1
RNase-Free DNase (Promega, USA) and heat inacti-
vated according to the manufacturer’s protocol. The
threshold cycle (CT) value for amplification of each
gene was determined by the auto threshold function of
the software. Prior to the amplification, the PCR
efficiency and primers compatibility for the gene of
interest and a reference gene were validated via the
standard curve method [10]. A melting curve analysis
with temperature ramping from 55°C–99°C was carried
out for each run to confirm the specificity of the PCR
amplifications. β-actin, which served as a reference
gene, was used for the normalization of the cDNA in-
put. Actb, B2M and Gusb served as housekeeping (HK)
genes.
Microarray analysis
Calculate the ΔCt for each pathway-focused gene in each
treatment group [11,12]: ΔCt (group 1) = average Ct –average of HK genes’ Ct for group 1 array; ΔCt (group
2) = average Ct – average of HK genes’ Ct for group 2
array. Calculate the ΔΔCt for each gene across two PCR
Arrays (or groups): ΔΔCt =ΔCt (group 2) - ΔCt (group
1), where group 1 is the control and group 2 is the
Figure 2 Comparison of cardiac function between ivabradine and control groups. M-model echocardiography showed a significant
increase of ventricular wall movement after ivabradine treatment (upper column); however, there was no significant difference in cardiac
function in the control group (lower column).
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from group 1 to group 2 as 2-ΔΔCt was calculated.
Immunohistochemical study
Animals hearts were fixed in 4% paraformaldehyde for
24 h, embedded in paraffin, and cross-sectioned into
10-mm slices. Sections were stained with hematoxylinTable 3 Genes with significantly higher expression (>2 times)
Gene name Function
MMP −2(matrix metallopeptidase- 2) ECM
MIP-3 β(macrophage inflammation protein-3 β, CCL 19) Lymphoid T c
6Ckine(chemokine with 6 cysteines,CCL21) Lymphoid org
ACE/CD143(angiogensin I Converting Enzyme/CD 143) RAAS







IL-17 F(interlukin-17 F) T cells
IL-1ra/IL-1 F3(interlukin-1ra/-1 F3) T cells
IL-2 Rα(interlukin-2 Rα) T cells
Fold changes are relative to normal samples.
FC, fold change; ECM, extracellular matrix; RAAS, renin angiotensin aldosterone sys
growth factor.and eosin (H&E) for cell alignment according to the
manufacturer’s instructions. Based on the results of the
microarray analysis, staining was performed to deter-
mine the expression of MMP-2, TGF-β, TIMP and P53.
The staining score was calculated based on the percent
positive area (no positive staining = 0; less than 25% = 1
point; 25–50% = 2 points; 51–75% = 3 points; and morein the ivabradine group than in the control group
IVBD (mean) Control (mean) FC P
0.027 0.067 0.40 0.031
ells 0.319 0.144 2.22 0.014
ans 0.421 0.177 2.37 0.024
0.433 0.189 2.29 0.006
0.327 0.123 2.66 0.047
0.292 0.086 3.39 0.016
0.245 0.089 2.75 0.021
0.212 0.067 3.16 0.020
0.333 0.159 2.09 0.005
0.173 0.0845 2.05 0.039
0.327 0.161 2.03 0.001
0.385 0.163 2.36 0.001
0.266 0.121 2.19 0.003
0.298 0.143 2.08 0.001
tem; TGF, tissue growth factor; TNF, tumor necrosis factor; EGF, epidermal
Table 4 Immunohistochemistry analysis
ivabradine (n = 6) Control (n = 6) P value
Matrix metalloproteinase-2
Staining score
Median (75% quartile)* 0.75 (1.00) 1.5 0(1.25) 0.048
Mean (95%CI) 0.75 (0.29-0.92) 1.2 (0.64-1.76) 0.032
Staining intensity, grade 1.9 ± 0.3 3.9 ± 0.3 0.022
Week +moderate, n(%) 4 (66) 1 (17) 0.043
Strong + very strong, n(%) 2 (14) 5 (83) 0.043
*Non-normal data distribution. Nonparametric analysis was used for the comparison between the two groups.
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(weak = 1; moderate = 2; strong = 3, and very strong =
4). Five fields of view were randomly selected for each
sample, and the average positive points for each case
were reported as the actual positive points.Western blot analysis
Cardiomyocytes were gently washed twice with ice-
cold PBS and lysed in a cocktail of RIPA buffer, pro-
teinase inhibitor and phosphatase inhibitor. After
20 min on ice, cells were scraped and lysates were
clarified by centrifugation at 12,000 x g for 15 min at
4°C. Protein concentrations were quantified by BCA
protein assay according to the manufacturer’s instruc-
tions. In total, 60 μg of protein were separated by a
10% SDS-PAGE gel and transferred to a PVDF mem-
brane before being incubated overnight at 4°C with a
primary antibody (caspase 3, BAX, NF-κB, MMP-2 and
β-actin). After that the membrane was washed and
incubated with a horseradish peroxidase-conjugated
secondary antibody for 1 hour at room temperature.
After a second wash, the membranes were developed
using an enhanced chemiluminescence substrate and
the band intensities were analyzed using ImageJ
(National Institutes of Health, Bethesda, USA).Figure 3 Comparison of MMP-2 staining before (A) and 3 months afte
significance (p = 0.048) (C).Statistical analysis
Data are presented as mean ± SD for continuous variables
and frequency for categorical variables. Comparison of
continuous variables was performed using the t test or
Mann–Whitney test as appropriate. The chi-square
test or Fisher's exact test was used to analyze categor-
ical variables. All statistical analyses were performed
using SPSS® software, version 17.0 (SPSS Inc., USA).
Statistical significance was set as P < 0.05.Results
Measurement of cardiac function by echocardiography
Indices of cardiac function were comparable between the
ivabradine and control groups (Table 2 and Figure 2).
Importantly, at the 3 month follow-up, IVSTs, LVDs,
LVPWs, eject fraction (EF) and fractional shortening (FS)
improved significantly in the ivabradine group (1.59 ±
0.03 mm, 1.65 ± 0.08 mm, 1.42 ± 0.09 mm, 75.7 ± 3.43%
and 49.33 ± 3.01 %, respectively) compared with the con-
trol group (1.41 ± 0.21 mm, p = 0.022; 2.22 ± 0.53 mm,
p = 0.017; 1.26 ± 0.14 mm, p = 0.032; 54.1 ± 8.3 %, p =
0.018; and 27.34 ± 4.87%, p < 0.001, respectively). Com-
pared with the baseline measurements, at 3 months after
administration of ivabradine, cardiac function was signifi-
cantly improved with the exception of the left ventricularr (B) ivabradine treatment. The difference in staining score reached
Figure 4 Western blot analysis of the phosphorylation state of caspase 3. Caspase 3 was dephosphorylated significantly in the ivabradine
group, compared with the control group.
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differences in echocardiographic measurements between the
baseline and the 3 month follow-up in the control group.Differentially expressed genes in the myocardium of
diabetic mice
According to microarray analysis, 15 genes were differ-
entially expressed in diabetic mice after ivabradine
treatment. Of these 15 genes, MMP-2 was down-
regulated (fold-change, defined as the ratio of control/
ivabradine, 2.459, p = 0.031), and the remaining 14
genes were up-regulated (Table 3).Functional gene sets that discriminate between
ivabradine and control groups
From these significant diabetic development genes, we have
been able to identify some specific functional groups.
MMP-2 is one member of the matrix metalloproteinase
family, which modulates the inflammatory system and
apoptosis. MMP-2 targeting at the extracellular matrix was
significantly inhibited by ivabradine. Lymphocyte prolifera-
tion induced by inflammation and immunity was markedly
promoted by ivabradine, and this was confirmed by the sig-
nificant up-regulation of 6Ckine, ACE/CD143, ALK-1, CT-Figure 5 Western blot analysis of the phosphorylation of BAX. BAX w
with the control group.1, CD27, endoglin, MIP-3β, epigen, IL-17E/F, IL-1ra/IL-
1 F3, and IL-2 Rα.Immunohistochemical study
Based on the microarray analysis, the up-regulation of
MMP-2 expression was analyzed by immunostaining,
and the results are shown in Table 4 and Figure 3. The
mean staining score and staining intensity in the ivabra-
dine group were significantly improved (2.1 ± 0.2 scores
and 1.9 ± 0.3 grade), compared with the control group
(3.6 ± 0.3 scores, p = 0.038 and 3.9 ± 0.3 grade, p = 0.022,
respectively).Western blot analysis
Based on the results of the microarray, we investigated
the phosphorylation of MMP-2 and several other pro-
teins involved in apoptosis, including NF-κB, caspase
3 and BAX. Phosphorylation of caspase 3 and BAX
was significantly reduced by ivabradine (Figure 4 and
Figure 5), consistent with the increased phosphorylation
of NF-κB after treatment by ivabradine (Figure 6). In line
with the microarray analysis, MMP-2 phosphorylation
was inhibited in ivabradine-treated rats (Figure 7) com-
pared with the control group.as dephosphorylated significantly in the ivabradine group, compared
Figure 6 Western blot analysis of the phosphorylation of NF-κB. Phosphorylation of NF-κB was increased significantly in the ivabradine
group, compared with the control group.
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The major findings of the present study are: (1) Ivabra-
dine treatment significantly inhibits the expression and
activity of MMP-2 in diabetic mice, (2) Ivabradine down-
regulates the phosphorylation of Caspase 3, BAX, but up-
regulats the phosphorylation of NF-kB in mice with
diabetes. Taken together, heart function of diabetic
nimals is improved significantly during Ivabradine treat-
ment, compared to control group.
A number of genes have been discovered as potential
candidates to cause T2D via the modulation of different
signal pathways mediated [13-24]. Cross-talk between
these signaling systems unravels the complexity of the
molecular mechanism of T2D.
Matrix metalloproteinases (MMPs) are a family of
zinc-binding proteolytic enzymes that normally remodel
the extracellular matrix and pathologically attack sub-
strates as part of an inflammatory response. The major
MMP species in the myocardium and vasculature are the
gelatinases (MMPs 2 and 9), MMP-1 (interstitial collage-
nase) and Mt1-MMP. Recently it has been proven that
matrix metalloproteinases (MMPs) play an important
role in atherosclerosis and the rebuilding of the vascular
wall [25]. The alteration of MMP-2 gene expression in-
duced by a 3 month ivabradine treatment, was associatedFigure 7 Western blot analysis of the phosphorylation of MMP-2. MM
with the control group.with an improvement of cardiac function in diabetic
mices, as confirmed by our immunohistochemistry and
Western blot analyses.
It has been found that high glucose concentration
promotes TGF-β expression and activates the Jak/
STAT signaling cascade in diabetic kidney cells. Activa-
tion of this signaling cascade can stimulate excessive
proliferation and the growth of glomerular mesangial
cells, contributing to diabetic nephropathy [14,15].
Exposure to high glucose concentrations has also been
shown to activate the MAPK signaling pathway in
skeletal muscle cells [16]. These findings were in
agreement with our finding that ivabradine improved
cardiac function by promoting the expression and ac-
tivity of endoglin. Endoglin is an auxiliary receptor for
the TGF-β receptor complex, which functions in
related signaling pathways and is mainly expressed in
vascular and connective tissues and in endothelial and
stromal cells [26,27]. Up-regulated endoglin expression
has been reported during wound healing and tumor
vascularization, and in inflammatory tissues and
developing embryos [26-28]. Mutations in endoglin
have been found to be a causal factor in hereditary
hemorrhagic telangiectasia (HHT), a disease character-
ized by the malformation of vascular structure [29,30].P-2 was dephosphorylated significantly in the ivabradine group, compared
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expression by ivabradine would be related to the
impairment of malformed vascular structure [29-31].
PI3K/Akt is a key molecule in insulin signaling that is
found to be down-regulated in T2D [20]. However,
there is a discrepancy in terms of the regulation of the
PI3K/Akt transduction pathway by ivabradine: up-
regulating eNOS expression independent of PI3K/Akt
pathway [5], inhibiting NADPH/ROS/RAAS but regu-
lating PI3K/Akt in ApoE−/− mice [6,7], limiting PI3K
activity and the phosphorylation of AKT in CD4-
positive lymphocytes [8]. We found that the expression
and activity of the epigen gene was up-regulated by
ivabradine treatment in diabetic myocardium. Epigen
encodes a protein of 152 amino acids that contains
EGF-like features. Epigen exhibits 24–37% sequence
identity with EGF, TGF, and epiregulin. EGF exerts
insulin-like effects on glucose transport and lipolysis
and can increase the tyrosine phosphorylation and
activation of IRS-1 and IRS-2. EGF is also capable of
activating additional PI3K pools, thereby augmenting
the downstream signaling of insulin in insulin-resistant
states like T2D [13]. As a result, the modulation of epi-
gen expression and activity by ivabradine via PI3K and
MAPK signaling [32] would be predicted to be associ-
ated with the improvement of cardiac function. Simi-
larly, MIP 3-β also regulated both the P38/MAPK and
PI3K/Akt signaling pathways [33-35]. However, there
was a lack of direct evidence of ivabradine regulating
the PI3K/Akt signaling system provided by our results,
as the change of Akt expression and Combo protein
were not significantly different between the ivabradine
and control groups.
Caspase 3 and BAX are two signals participating in
the process of apoptosis [35,36]. Our study showed
that ivabradine was associated with the significant de-
phosphorylation of caspase 3 and BAX, indicating the
anti-apoptotic effect of ivabradine in diabetic animals.
In contrast, NF-κB was activated by ivabradine, and
phosphorylated NF-κB would promote protein synthe-
sis and thus inhibit apoptosis [37]. These results would
provide additional evidences of anti-ischemic effect by
ivabradine for diabetic setting, in line with previously
published results confirming the cardioprotective
effect by ivabradine for patients with ischemic heart
disease [38,39].
Limitation
Obviously, the current study did not analyze the mech-
anism attributive to the signal pathways in which ivabra-
dine involved. For example, the question why NF-kB
was activated by ivabradine was not studied. Another
limitation was small sample size, which would be ex-
panded in our next study. Finally, we did not performedWestern Blotting analysis for all differentially expressed
genes, which would be at least mask the potential of
cross-talking by different signal pathways.
Conclusion
Our study for the time reported the cardioprotective
effect by ivabradine in diabetic animal. The major find-
ing would be implied the possible benefits of ivabradine
for diabetic patients. As a result, further clinical study is
required in order to elucidate the efficacy and safety of
ivabradine for Type 2 diabetes.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors have read and approved this submission. SLC designed this
study, participated in the data analysis, and wrote this manuscript. ZYH
carried out animal study, participated in the statistical analysis and writing.
GFZ participated in the measuring mRNA and data analysis. MHL carried
out microarray analysis and data analysis. BL carried out feeding animal,
microarray analysis and signal pathways.
Acknowledgments
The authors would like to thank Yan Liu and Sheng-Xia Zhang for their excellent
technical assistance during this study, Mrs. Zhi-Mei Wang for secretarial assistance
and Miss Zu-Ling Xu for editorial assistance with the paper.
Author details
1Department of Cardiology, Nanjing First Hospital, Nanjing Medical
University, 68 Changle Road, Nanjing 210006, China. 2Department of
Cardiology, Nanjing Heart Center, Nanjing, China. 3Third Clinical Medical
College, Nanjing Medical University, Nanjing, China. 4Nanjing Medical
University, Nanjing, China.
Received: 29 August 2014 Accepted: 17 October 2014
Published: 31 October 2014
References
1. Van den Oever IAM, Raterman HG, Nurmohamed MT, Simsek S: Endothelial
dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators
Inflamm 2012, 792393.
2. Ramachandran A, Snehalatha C, Viswanathan V: Burden of type 2 diabetes
and its complications- the Indian scenario. Curr Sci India 2002,
83:1471–1476.
3. Mazzone T, Chait A, Plutzky J: Cardiovascular disease risk in type 2
diabetes mellitus: insights from mechanistic studies. Lancet 2008,
371:1800–1809.
4. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas
PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz
HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL,
Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams
SV, Anderson JL: ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the
diagnosis and management of patients with stable ischemic heart
disease: a report of the American college of cardiology foundation/
American Heart Association task force on practice guidelines, and the
American college of physicians, American Association for thoracic
surgery, preventive cardiovascular nurses association, society for
cardiovascular angiography and interventions, and society of thoracic
surgeons. Circulation 2012, 126:e354.
5. Borer JS: Drug insight: If inhibitors as specific heart-rate-reducing agents.
Nat Clin Pract Cardiovasc Med 2004, 1:103–109.
6. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC:
Chronic heart rate reduction by ivabradine prevents endothielial
dysfunction in dyslipidaemic mice. Br J Pharmacol 2008, 154:749–757.
7. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H: Role of
oxidative stress in atherosclerosis. Am J Cardiol 2003, 91:7A–11A.
Chen et al. BMC Cardiovascular Disorders 2014, 14:150 Page 10 of 10
http://www.biomedcentral.com/1471-2261/14/1508. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U:
Heart rate reduction by ivabradine reduces oxidative stress, improves
endothelial function, and prevents atherosclerosis in apolipoprotein
E-deficient mice. Circulation 2008, 117:2377–2387.
9. Walcher T, Bernhardt P, Vasic D, Bach H, Durst R, Rottbauer W, Walcher D:
Ivabradine reduces chemokine-induced CD4-positive lymphocyte
migration. Mediators Inflamm 2010, 751313.
10. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, Picard
MH, Polk DM, Ragosta M, Parker Ward R, Weiner RB: ACCF/ASE/AHA/ASNC/
HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate use criteria for
echocardiography. A report of the American college of cardiology
foundation appropriate use criteria task force, American society of
echocardiography, American heart association, American society of
nuclear cardiology, heart failure society of america, heart rhythm society,
society for cardiovascular angiography and interventions, society of
critical care medicine, society of cardiovascular computed tomography,
and society for cardiovascular magnetic resonance endorsed by the
American college of chest physicians. J Am Coll Cardiol 2011,
57:1126–1166.
11. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 22DDCT method. Methods 2001,
25:402–408.
12. Yuan JS, Reed A, Chen F, Stewart CN Jr: Statistical analysis of real-time PCR
data. BMC Bioinformatics 2006, 7:85–87.
13. Gogg S, Smith U: Epidermal growth factor and transforming growth
factor alpha mimic the effects of insulin in human fat cells and augment
downstream signalling in insulin resistance. J Biol Chem 2002,
277:36045–36051.
14. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC: Role of the JAK/STAT
signalling pathway in diabetic nephropathy. Am J Physiol Renal Physiol
2006, 290:F762–F768.
15. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB: Inhibition of the Jak/STAT
signalling pathway prevents the high glucose-induced increase in tgf-
beta and fibronectin synthesis in mesangial cells. Diabetes 2002,
51:3505–3509.
16. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC,
Tesch GH: Abnormal p38 mitogen-activated protein kinase signalling in
human and experimental diabetic nephropathy. Diabetologia 2004,
47:1210–1222.
17. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M: Increased vascular
endothelial growth factor expression but impaired vascular endothelial
growth factor receptor signalling in the myocardium of type 2 diabetic
patients with chronic coronary heart disease. J Am Coll Cardiol 2005,
46:827–834.
18. Das UN, Rao AA: Gene expression profile in obesity and type 2 diabetes
mellitus. Lipids Health Dis 2007, 6:35–39.
19. Burgermeister E, Seger R: MAPK kinases as nucleo-cytoplasmic shuttles for
PPARgamma. Cell Cycle 2007, 6:1539–1548.
20. Jiang G, Zhang BB: Pi 3-kinase and its up- and down-stream modulators
as potential targets for the treatment of type II diabetes. Front Biosci
2002, 7:d903–d907.
21. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X: Wnt signalling
regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A 2007,
104:6247–6252.
22. Ho E, Bray TM: Antioxidants, NFkappaB activation, and diabetogenesis.
Proc Soc Exp Biol Med 1999, 222:205–213.
23. Zhao J, Zhang N, He M, Yang Z, Tong W: Increased beta-cell apoptosis
and impaired insulin signalling pathway contributes to the onset of
diabetes in OLETF rats. Cell Physiol Biochem 2008, 21:445–454.
24. Hadi HA, Suwaidi JA: Endothelial dysfunction in diabetes mellitus. Vasc
Health Risk Manag 2007, 3:853–876.
25. Beaudeux JL, Giral P, Brukert E: Matrix metalloproteinases and
atherosclerosis. Therapeutic aspects. Annu Biol Clinic 2003, 61:147–158.
26. Bernabeu C, Conley BA, Vary CP: Novel biochemical pathways of endoglin
in vascular cell physiology. J Cell Biochem 2007, 102:1375–1388.
27. Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of
endoglin via mitogen-activated protein kinases in mouse brain
microvascular endothelial cells. Stroke 2003, 34:2483–2488.
28. Quintanilla M, Ramirez JR, Pérez-Gómez E, Romero D, Velasco B, Letarte M,
López-Novoa JM, Bernabéu C: Expression of the TGF-beta coreceptorendoglin in epidermal keratinocytes and its dual role in multistage
mouse skin carcinogenesis. Oncogene 2003, 22:5976–5985.
29. Ten Dijke P, Goumans MJ, Pardali E: Endoglin in angiogenesis and vascular
diseases. Angiogenesis 2008, 11:79–89.
30. Fernández-L A, Sanz-Rodriguez F, Blanco FJ, Bernabéu C, Botella LM:
Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the
TGF-beta signaling pathway. Clinic Med Res 2006, 4:66–78.
31. Kopczyńska E, Makarewicz R: Endoglin – a marker of vascular endothelial
cell proliferation in cancer. Contemp Oncol 2012, 16:68–71.
32. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA: The epidermal growth factor
receptors and their family of ligands: their putative role in
atherogenesis. Atherosclerosis 2006, 186:38–53.
33. Chen ML, Lin YH, Yang CM, Hu ML: Lycopene inhibits angiogenesis both
in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-
mediated PI3K-Akt and ERK/p38 signaling pathways. Mol Nutr Food Res
2012, 56:889–899.
34. Zhao ZJ, Liu FY, Li P, Ding X, Zong ZH, Sun CF: CCL19-induced chemokine
receptor-7 activates the phosphoinositide-3 kinase-mediated invasive
pathway through Cdc42 in metastatic squamous cell carcinoma of the
head and neck. Oncol Republ 2011, 25:729–737.
35. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream.
Cell 2007, 129:1261–1274.
36. Baltadzhiev IG, Delchev SD: Changes of Bcl-2, Bax and Caspase-3
expression in the dermal microvascular endothelial cells and the
epidermal layers of the eschar (tache noire) in patients with
Mediterranean spotted fever. Folia Histochem Cytobiol 2013, 51:121–126.
37. Wang PH, Gu ZH, Wan DH, Liu BD, Huang XD, Weng SP, Yu XQ, He JG:
The shrimp IKK-NF-κB signaling pathway regulates antimicrobial peptide
expression and may be subverted by white spot syndrome virus to
facilitate viral gene expression. Cell Mol Immunol 2013, 10:423–436.
38. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R: Effect of
ivabradine in patients with left-ventricular systolic dysfunction: a pooled
analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
Eur Heart J 2013, 34:2263–2270.
39. Komajda M, Böhm M, Borer JS, Ford I, Robertson M, Manolis AJ, Tavazzi L,
Swedberg K, SHIFT Investigators: Efficacy and safety of ivabradine in
patients with chronic systolic heart failure according to blood pressure
level in SHIFT. Eur J Heart Fail 2014, 16:810–816.
doi:10.1186/1471-2261-14-150
Cite this article as: Chen et al.: I(f) current channel inhibitor (ivabradine)
deserves cardioprotective effect via down-regulating the expression of
matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic
mice. BMC Cardiovascular Disorders 2014 14:150.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
